1 citations,
April 2009 in “Journal of Intellectual Property Law & Practice” UK courts and the European Patent Office are now more open to granting patents for new dosage regimes.
November 2022 in “Journal of Investigative Dermatology” 3D skin bioprinting, using skin bioinks like collagen and gelatin, is growing fast and could help treat wounds, burns, and skin cancers, as well as test cosmetics and drugs.
September 2021 in “Assay and drug development technologies” Drug repurposing shows promise for treating many medical conditions.
July 2007 in “Journal of Generic Medicines” The UK High Court revoked Lundbeck's patent for Escitalopram, and second medical use claims based on dosage were not considered novel.
January 2006 in “Journal of Clinical Dermatology” 2 citations,
October 2004 in “Organic Process Research & Development” The document reviews 20 U.S. patents from July and August 2004 about new drug forms, cancer treatments, aroma chemicals, statin drugs, and various chemical production methods.
10 citations,
August 1998 in “Journal of Investigative Dermatology” The compounds tested could potentially treat hair loss and alopecia.
October 2022 in “Biomedicines” Finasteride in male rats causes liver and metabolic issues in their offspring.
2 citations,
November 2014 in “Pharmaceutical Patent Analyst” Recent legal rulings favored Genentech, Teva, and upheld guidelines for patent term extensions.
July 2008 in “Journal of Intellectual Property Law & Practice” The UK Court of Appeal ruled that new dosing regimens for drugs can be patented, aligning with the European Patent Office's approach.
2 citations,
September 2012 in “Pharmaceutical patent analyst” European patent law now allows patents for new uses and dosages of known drugs, but protection scope is unclear.
1 citations,
January 2017 in “Social Science Research Network” The document suggests creating a secure database for indigenous knowledge and recommends that the TKDL actively fight patents that slightly alter traditional knowledge.
November 2008 in “Journal of Generic Medicines” The document updates on EU legal changes, including pharmaceutical patents, class actions in Italy, and various drug-related rulings.
18 citations,
July 2011 in “Journal of The American Academy of Dermatology” Familial factors affect hair loss types in Koreans, with M type in men, L type in women, and paternal factors influencing male hair loss more.
November 2007 in “Journal of Generic Medicines” Europe strengthened medicine regulations, increased protection against counterfeit drugs, and made it tougher to challenge comparative advertising, while also focusing on patent law enforcement and updating plant protection rules.
February 2018 in “Medical Hypotheses” Male pattern hair loss may have evolved to promote younger fathers for offspring health and survival, encouraging monogamy and paternal nurturing.
8 citations,
January 2013 in “International Journal of Trichology” The BASP classification is effective for diagnosing pattern hair loss in Indian men and women.
5 citations,
May 2017 in “International Journal of Research in Dermatology” Early onset hair loss in young men is common and linked to family history and alcohol use.
November 2013 in “대한피부과학회지” Eating habits may affect the duration of male pattern baldness.
April 2013 in “Journal of the American Academy of Dermatology” Diabetic patients often have ingrown nails due to obesity, high blood pressure, past injuries, bad nail trimming, nail fungus, weak foot pulse, and weak knee reflex.
Iron supplements may reverse premature graying in iron-deficient individuals; ingrown nails are common in diabetics with certain risk factors; topical finasteride may reduce scalp DHT as effectively as oral finasteride; monilethrix treatment is challenging but some medications can help.
23 citations,
November 2001 in “Archives of Dermatology” Genetic discoveries are key for understanding, diagnosing, and treating inherited hair and nail disorders.
16 citations,
April 2011 in “Recent Patents on Inflammation & Allergy Drug Discovery” Alopecia Areata is an autoimmune disease causing hair loss in patches, often starting before age 20, and while some cases recover on their own, treatments include topical corticosteroids, minoxidil, and promising new methods like IL-31 antibodies and 308-nm Excimer laser therapy.
9 citations,
November 2009 in “Recent Patents on Drug Delivery & Formulation” Microemulsions could improve how drugs are delivered and absorbed in the body.
5 citations,
October 2012 in “Journal of Midwifery & Women's Health” Healthcare providers should start with simple fertility tests and treatments before referring patients to specialists.
4 citations,
August 2020 in “Journal of Cosmetic Dermatology” QR 678 and QR678 Neo treatments are effective for hair loss in women with PCOS.
August 2023 in “Journal of Cosmetic Dermatology” QR678 Neo® improved seborrheic dermatitis symptoms in a small group of patients.
11 citations,
August 1997 in “Expert Opinion on Therapeutic Patents” Many potential alopecia treatments need more testing to confirm they promote acceptable hair growth with minimal side effects.
1 citations,
May 2006 in “Expert Opinion on Therapeutic Patents” No FDA-approved treatments for chemotherapy-induced hair loss existed in 2006; more research was needed.
1 citations,
January 2003 in “Expert Opinion on Therapeutic Patents” Steroid sulfatase inhibitors could potentially treat hormone-related disorders like certain cancers, hair loss, acne, and improve cognitive dysfunction.